Raviprakash Makam, MD
Internal Medicine · Anaheim, CANPI 1720070527
Payments from drug & device makers
Across 694 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Novartis$1K
- Esperion Therapeutics, Inc.$1K
- Amgen$1K
- Bayer$1K
- plus $6K from 35 others
What the payments were for
- Consulting fees$6004%
- Food & beverage$13,92996%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,678 |
| GSK | 62 | $1,660 |
| Novartis | 141 | $1,453 |
| Esperion Therapeutics, Inc. | 68 | $1,260 |
| Amgen | 67 | $1,212 |
| Bayer | 33 | $1,166 |
| Edwards Lifesciences | 32 | $997 |
| Johnson & Johnson | 37 | $777 |
| E.r. Squibb & Sons, L.L.C. | 36 | $708 |
| Novo Nordisk | 29 | $534 |
| Lilly USA, LLC | 21 | $464 |
| Boehringer Ingelheim | 13 | $300 |
| Pfizer | 11 | $284 |
| Boston Scientific | 7 | $271 |
| Kowa Pharmaceuticals America, Inc. | 14 | $237 |
| Merck | 10 | $229 |
| Abbott | 2 | $188 |
| Actelion Pharmaceuticals US, Inc. | 12 | $168 |
| Kestra Medical Technology Services, Inc. | 5 | $130 |
| Regeneron Healthcare Solutions, Inc. | 5 | $126 |
| Medicure Pharma Inc. | 1 | $85 |
| Medtronic | 1 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Scpharmaceuticals Inc. | 2 | $41 |
| AbbVie | 2 | $39 |
| Atricure, Inc. | 1 | $37 |
| Shield Therapeutics Inc | 1 | $37 |
| Gilead | 2 | $35 |
| Ironwood Pharmaceuticals, Inc | 2 | $34 |
| Abiomed | 1 | $25 |
| Heartflow, Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Baxter Healthcare | 1 | $22 |
| Venclose Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Coala Life Inc | 1 | $19 |
| Philips North America LLC | 1 | $16 |
| Optos, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$600
- BREZTRI$380
- AREXVY$239
- MitraClip System$162
- SAPIEN 3 Ultra RESILIA$159
- FARXIGA$125
- NEXLIZET$125
- NEXLETOL$125
- Repatha$122
- ENTRESTO$121
- ELIQUIS$121
- Edwards SAPIEN 3 Transcatheter Heart Valve$110
- XARELTO$104
- GENERAL - THERAPIES$101
How this compares
$14,560 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $88,124 |
| KerendiaFinerenone | 100 | $83,094 |
| OzempicSemaglutide | 57 | $70,472 |
| EntrestoSacubitril/Valsartan | 56 | $69,827 |
| MounjaroTirzepatide | 59 | $59,379 |
| Repatha SureclickEvolocumab | 87 | $47,323 |
| FarxigaDapagliflozin Propanediol | 51 | $41,042 |
| XareltoRivaroxaban | 55 | $40,240 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $40,229 |
| TrulicityDulaglutide | 38 | $38,392 |
| VerquvoVericiguat | 38 | $32,601 |
| LokelmaSodium Zirconium Cyclosilicate | 26 | $26,116 |
| LinzessLinaclotide | 41 | $23,398 |
| JanuviaSitagliptin Phosphate | 28 | $22,789 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $22,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma, Breztri Aerosphere, Brilinta | $1,678 | $100,850119 claims |
| Lilly USA, LLCMounjaro, Trulicity | $464 | $97,77197 claims |
| PfizerEliquis | $284 | $88,124105 claims |
| Novo NordiskOzempic, Rybelsus | $534 | $85,79074 claims |
| BayerKerendia | $1,166 | $83,094100 claims |
| NovartisEntresto | $1,453 | $69,82756 claims |
| MerckVerquvo, Januvia | $229 | $55,38966 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $1,660 | $48,56990 claims |
| Johnson & JohnsonXarelto | $777 | $40,24055 claims |
| AbbVieLinzess | $39 | $23,39841 claims |
| Boehringer IngelheimJardiance | $300 | $22,34421 claims |
| Esperion Therapeutics, Inc.Nexlizet | $1,260 | $20,87128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Anaheim
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.